Table 2.
Survival durations for glycogen-rich clear cell (GRCC) carcinoma patients.
| Median (Months) | 95% CI | p-Value | |||
|---|---|---|---|---|---|
| Lower | Upper | ||||
| All GRCC cases | 158 | 96.5 | 219.5 | NA | |
| Age | 60 years and under | 158 | 96.6 | 219.4 | 0.002 |
| >60 year | 73 | 18.6 | 127.4 | ||
| Sex | Female | - | - | - | 0.56 |
| Male | 81 | 62.5 | 99.5 | ||
| Race | American Indian/Alaska Native | 27 | - | - | 0.16 |
| Asian or Pacific Islander | - | - | - | ||
| Black | - | - | - | ||
| White | 111 | 45.6 | 176.4 | ||
| Grade | Well to Moderately Differentiated | 162 | 105.1 | 218.9 | 0.19 |
| Poorly Differentiated to Anaplastic | 111 | - | - | ||
| ER Status | Negative | 158 | 69.3 | 246.7 | 0.82 |
| Positive | 174 | 61.2 | 286.8 | ||
| PR Status | Negative | 158 | 86.3 | 229.7 | 0.15 |
| Positive | - | - | - | ||
| AJCC Stage | I | 162 | 125.7 | 198.3 | <0.001 |
| II | - | - | - | ||
| III | 69 | 38.4 | 99.6 | ||
| IV | 30 | 7.9 | 52.1 | ||
| T | T1 | 158 | 125.4 | 190.6 | 0.005 |
| T2 | - | - | - | ||
| T3 | 27 | - | - | ||
| T4 | 25 | - | - | ||
| N | N0 | 174 | - | - | 0.001 |
| N1 | 81 | 15.3 | 146.7 | ||
| N2 | 69 | - | - | ||
| N3 | 50 | 12.3 | 87.7 | ||
| M | M0 | 162 | 121.1 | 202.9 | <0.001 |
| M1 | 30 | 7.9 | 52.1 | ||
| Surgery | No Surgery | 25 | 0.0 | 58.1 | <0.001 |
| Surgery | 158 | 100.4 | 215.6 | ||
| Extent of Surgery | No Surgery | 25 | 0.0 | 58.1 | 0.02 |
| Sub-Mastectomy # | 174 | 116.0 | 232.0 | ||
| Mastectomy | 108 | - | - | ||
| Radiation | No Radiation | 81 | 40.4 | 121.6 | 0.012 |
| Radiation | - | - | - | ||
HER2 Status was only available for cases diagnosed after 2010 and was therefore excluded from the analysis. Bolded are statistically significant p-values. “-” Median survival time not reached or could not be calculated. # Defined as any surgery less aggressive than total mastectomy. CI—confidence interval; ER—estrogen receptor; PR—progesterone receptor; AJCC—American Joint Committee on Cancer; NA—not applicable; T, N, M refers to tumor size, nodal status, and metastasis classifications of malignant tumor staging system, respectively.